Literature DB >> 32178817

Transforming growth factor beta (TGF-β) activity in immuno-oncology studies.

Gabriel Gallo-Oller1, Marianna Di Scala2, Fernando Aranda3, Javier Dotor4.   

Abstract

Transforming growth factor beta (TGF-β) is a potent pleiotropic polypeptide cytokine, with a complex and context dependent control of its activation, signaling and effector functions. This cytokine is pivotal in the regulation of immunological responses, tumor initiation and development, stromal homeostasis and all their intricate related interactions. Last decade advances in cancer immunotherapy have reactivated the clinical interest on potential drug with TGF-β inhibition effect, combined with immunomodulating enhancer drugs. The correct quantification of the in vitro and in vivo biological activity of this cytokine is essential to understand the intrinsic underlying biological mechanisms and TGF-β role in the immune system, tumor and stromal codevelopment, modulation and interactions. There is a wide variety of available procedures to quantify TGF-β activity, which includes different methodological approximations like ELISA, Bioassays including reporter gene assays, Flow cytometry (FC), Western blotting (WB), immunochemical/fluorescence microscopy, among others. Here, we detail available methods for TGF-β biological activity analysis, together with their applicability and suitability for each experimental setting, in order to get a complete analytical perspective and more comprehensive information along the development and design of combined antitumor immunotherapies, which include the inhibition of TGF-β biological activity.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bioassays; Biological activity; Cytometry; ELISA; Immunotherapy; Transforming growth factor beta; Tumor development; Western blot

Mesh:

Substances:

Year:  2019        PMID: 32178817     DOI: 10.1016/bs.mie.2019.06.008

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  3 in total

1.  Increased Serum Expression of Inflammatory Cytokines may Serve as Potential Diagnostic Biomarker for Bilirubin Encephalopathy.

Authors:  Hanzhou Guan; Chenghu Wang; Xinhua Zhang
Journal:  Clinics (Sao Paulo)       Date:  2020-11-30       Impact factor: 2.365

2.  Hotspots and Frontiers in Inflammatory Tumor Microenvironment Research: A Scientometric and Visualization Analysis.

Authors:  Yuli Zhang; Long Huo; Zhenzhen Wei; Qingfeng Tang; Hua Sui
Journal:  Front Pharmacol       Date:  2022-03-17       Impact factor: 5.810

3.  P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model.

Authors:  Sebastián Cruz-Morande; Javier Dotor; Mikel San-Julian
Journal:  Curr Oncol       Date:  2022-04-12       Impact factor: 3.109

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.